All Stories

  1. An Assessment of the Antidepressant Potential of Deramciclane in Two Animal Tests
  2. The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?
  3. Cannabidiol, cognition and schizophrenia: a narrative review
  4. Adjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety
  5. Letters to the Editor: Author reply to Letters to the Editor regarding ‘A challenge to the dopamine orthodoxy in schizophrenia?’
  6. Treatment of Brain Fog of Long COVID Syndrome: A Hypothesis
  7. A challenge to the dopamine orthodoxy in schizophrenia?
  8. Editorial: Role of the serotonergic system in pathology of major depressive disorders
  9. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
  10. Diagnostic agreement and concordance between consultation-liaison psychiatry and non-psychiatric (medical and surgical) doctors: changes within junior doctor’s terms
  11. Desvenlafaxine in the treatment of major depression: an updated overview
  12. Agomelatine for depression: expanding the horizons?
  13. Problematic medical marijuana, but not all cannabinoids?
  14. One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate
  15. Impairments of Spatial Working Memory and Attention Following Acute Psychosocial Stress
  16. Agomelatine, melatonin and depressive disorder
  17. Pharmacological Treatment of Panic Disorder
  18. The effect of agomelatine on 5HT2C receptors in humans: a clinically relevant mechanism?
  19. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006
  20. The Decline and Fall of the Psychopharmacology Empire?
  21. Duloxetine in the acute and continuation treatment of major depressive disorder
  22. Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessive–compulsive disorder
  23. Contemporary Therapies for Depression in Older People
  24. Continuation treatment of major depressive disorder: is there a case for duloxetine?
  25. Dysfunctional Circadian Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches
  26. Melatonin: hormone of the night
  27. Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects
  28. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5‐HT1Areceptor agonist
  29. Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder
  30. Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals
  31. Duloxetine in the treatment of generalized anxiety disorder
  32. The Impact of a Changed Environment on Arousal Levels of Patients in a Secure Extended Rehabilitation Facility
  33. Quetiapine augmentation in depressed patients with partial response to antidepressants
  34. Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication
  35. Friday Abstracts
  36. How does your garden grow—therapeutic principles from herbal remedies?
  37. The neurobiology of benzodiazepine receptors in panic disorder and post‐traumatic stress disorder
  38. An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers
  39. P.2.c.010 Quetiapine augmentation in depressed patients with partial or no response to antidepressants
  40. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder
  41. Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression
  42. Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature review
  43. Emerging treatments for major depression
  44. Neuropsychological study of underweight and “weight-recovered” anorexia nervosa compared with bulimia nervosa and normal controls
  45. An open-label study of quetiapine in anorexia nervosa
  46. Human Embryonic Stem Cells: A Resource for In Vitro Neuroscience Research?
  47. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins
  48. Prospects for the Treatment of Depression
  49. Prospects for the treatment of depression
  50. A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients
  51. Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder
  52. Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats
  53. Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists
  54. Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers
  55. Effect of Sodium Valproate on Nocturnal Melatonin Sensitivity to Light in Healthy Volunteers
  56. Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?
  57. Serotonergic and Dopaminergic Systems in Anorexia Nervosa: A Role for Atypical Antipsychotics?
  58. Fifth World Congress on Stress, London, 18–19 June 2004
  59. Prolactin response to d-fenfluramine in combat-related post-traumatic stress disorder
  60. An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat
  61. The emerging role of pharmacogenetics: implications for clinical psychiatry
  62. The Emerging Role of Pharmacogenetics: Implications for Clinical Psychiatry
  63. Mechanism of action of mirtazapine: dual action or dual effect?
  64. Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women
  65. Blunted growth hormone response to clonidine in post-traumatic stress disorder
  66. New Formulations of Existing Antidepressants
  67. The treatment of depression with different formulations of venlafaxine: a comparative analysis
  68. Blunted prolactin response to ?-fenfluramine in post-stroke major depression
  69. Olanzapine in Anorexia Nervosa
  70. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers
  71. Brain monoamines and early visual information-processing speed
  72. Olanzapine excretion in human breast milk: estimation of infant exposure
  73. Guest Editorial: International Society for the Investigation of Stress (ISIS)
  74. Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers
  75. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes
  76. Book Review: Therapeutic Guidelines: Psychotropic, Version 4
  77. Sertraline Analysis in the Plasma of Breast-Fed Infants
  78. The effect of single oral doses of zopiclone on nocturnal melatonin secretion in healthy male volunteers
  79. Mechanisms underlying the speed of onset of antidepressant response
  80. Third-Generation Antidepressants
  81. Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients
  82. Book Review: Differential Effects of Antidepressants
  83. Differential effects of antidepressants
  84. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography
  85. Antidepressants and Breast-Feeding
  86. Acute increases in night-time plasma melatonin levels following a period of meditation
  87. The effect of gender on the melatonin suppression by light: a dose response relationship
  88. Pindolol Augmentation of Antidepressants: A Review and Rationale
  89. Stress induced animal models of depression
  90. The benzodiazepines: a brief review of pharmacology and therapeutics
  91. Sertraline in paired blood plasma and breast-milk samples from nursing mothers
  92. A positron emission tomography study of benzodiazepine receptors in post-traumatic stress disorder
  93. An open label trial of venlafaxine in war veterans with chronic post traumatic stress disorder
  94. Frontal-subcortical circuits in obsessive-compulsive disorder: Role of the dopamine D1receptor
  95. Presence of olanzapine in breast milk
  96. The Test Re-Test Reliability of the Melatonin Suppression by White Light
  97. Melatonin Sensitivity to Dim White Light in Affective Disorders
  98. Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography
  99. Book Review: Drugs, the Brain and Behaviour: The Pharmacology of Abuse and Dependence
  100. The Evaluation of Depression in Inpatients with HIV Disease
  101. Onset of the Effects of the 5-HT1A Antagonist, WAY-100635, Alone, and in Combination With Paroxetine, on Olfactory Bulbectomy and 8-OH-DPAT–Induced Changes in the Rat
  102. The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light
  103. The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light
  104. Book Review: Psychotropic Drug Handbook, 7th ed.
  105. Book Review: Handbook of Essential Psychopharmacology
  106. Book Review: Psychotropic Drug Handbook, 7th ed. Paul J. Perry, Bruce Alexander and Barry I. Liskow
  107. Effect of the menstrual cycle stage on the melatonin suppression by dim white light
  108. Melatonin sensitivity to dim white light in different seasons
  109. Melatonin sensitivity to dim white light in different seasons
  110. Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors
  111. Treatment of Anxiety During Pregnancy
  112. (+)-S-20499 – a potential antidepressant? A behavioural and neurochemical investigation in the olfactory bulbectomised rat
  113. Plasma and human milk concentrations of moclobemide in nursing mothers
  114. Plasma and human milk concentrations of moclobemide in nursing mothers
  115. Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder
  116. Neurochemical effects of the enantiomers of mirtazapine in normal rats
  117. Evidence for 5-HT1A receptor control of pineal melatonin concentrations in the rat
  118. Combining pindolol and paroxetine in an animal model of chronic antidepressant action—can early onset of action be detected?
  119. Modulation of plasma melatonin concentrations by changes in posture
  120. The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat
  121. Negative symptoms, depression and parkinsonian symptoms in chronic, hospitalised schizophrenic patients
  122. Platelet paroxetine binding in post-traumatic stress disorder
  123. Book Review: The Psychopharmacologists. Interviews by Dr David Healy. Altman, Chapman and Hall, London, 1996. No. of Pages: 633. Price £45.
  124. Book Review: The Psychopharmacologists. Interviews by Dr David Healy. Altman, Chapman and Hall, London, 1996. No. of Pages: 633. Price £45.
  125. Panic in Australia
  126. 5. Benzodiazepines in anxiety disorders: managing therapeutics and dependence
  127. The effect of atenolol, a p!‐adrenergic antagonist, on nocturnal plasma melatonin secretion: Evidence for a dose‐response relationship in humans
  128. 3. Assessment of anxiety and depression in primary care
  129. The Psychopharmacologists
  130. ANTIDEPRESSANTS: CLINICAL ASPECTS
  131. Mood disturbance as a comorbid condition in schizophrenia: Etiology and treatment
  132. The effect of dim light on suppression of nocturnal melatonin in healthy women and men
  133. Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia
  134. Nocturnal plasma melatonin concentrations in healthy volunteers: Effect of single doses of d‐fenfluramine, paroxetine, and ipsapirone
  135. Successful treatment of serotonin syndrome with chlorpromazine
  136. Platelet paroxetine binding in post-traumatic stress disorder
  137. Overnight human plasma melatonin, Cortisol, prolactin, TSH, under conditions of normal sleep, sleep deprivation, and sleep recovery
  138. Letter
  139. Platelet [3H]-paroxetine binding in obsessive-compulsive disorder
  140. Platelet [3H]paroxetine binding in panic disorder
  141. Who bears the costs of antidepressants in Australia?
  142. A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
  143. Suicide, violent behaviour and fluoxetine
  144. Fast-Acting Antidepressants
  145. Definition and differential diagnosis of treatment-resistant depression
  146. Serotonergic function in panic disorder: Endocrine responses to d-Fenfluramine
  147. Differential Diagnosis and Drug Treatment of Panic Disorder, Anxiety and Depression
  148. Isoniazid and antidepressants
  149. Neuroendocrine responses to single doses of buspirone in obsessive-compulsive disorder
  150. Long-term management of depressive disorders
  151. Mianserin in breast milk [letter]
  152. Pharmacokinetic aspects of antidepressant treatment in the elderly
  153. Fluoxetine — Delayed half‐life and an Adverse Event
  154. A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness
  155. Prolactin response to dl-fenfluramine in panic disorder
  156. Plasma and breast milk concentrations of dothiepin and northiaden in lactating women
  157. Long-term drug treatment of panic disorder
  158. Alterations to Plasma Melatonin and Cortisol After Evening Alprazolam Administration in Humans
  159. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine
  160. Buspirone and Fluoxetine in the Treatment of OCD
  161. Stress and isatin: Effects on the serotonergic system
  162. Melatonin, cortisol and prolactin response to acute nocturnal light exposure in healthy volunteers
  163. Relationship of symptomatology of schizophrenia and tardive dyskinesia
  164. New Pharmacological Approaches to the Management of Depression: From Theory to Clinical Practice
  165. SEROTONERGIC FUNCTION IN PANIC DISORDER
  166. Fenfluramine Augmentation of Clomipramine Treatment of Obsessive Compulsive Disorder
  167. A short‐term open trial of clomipramine in the treatment of patients with panic attacks
  168. Psychological adjustment following traumatic spinal cord injury: a study using the psychosocial adjustment to illness scale
  169. Breastfeeding and the use of psychotropic medication: a review
  170. High-affinity platelet [3H]LSD binding is decreased in panic disorder
  171. A Portable Light Source for Bright Light Treatment
  172. Pharmacokinetic and Pharmacodynamic Effects of a Single Nocturnal Dose of Alprazolam
  173. Platelet MAO and 5–HT uptake in agoraphobics
  174. Melatonin supersensitivity to dim light in seasonal affective disorder
  175. Serotonergic effects of isatin: an endogenous MAO inhibitor related to tribulin
  176. Pharmacotherapy of Panic Disorder
  177. Short-acting versus long-acting benzodiazepines: Discontinuation effects in panic disorders
  178. A Short Term Open Clinical Trial of Clobazam in the Treatment of Patients with Panic Attacks
  179. Platelet serotonin uptake in panic disorder patients: A replication study
  180. Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience
  181. PANIC ATTACKS, BUSPIRONE, AND SEROTONIN FUNCTION
  182. Platelet serotonin response to treatment in geriatric depression
  183. Platelet serotonin uptake and 3H-imipramine binding in panic disorder
  184. Human Melatonin Suppression by Light is Intensity Dependent
  185. Antidepressant Drug Measurement: Review of Methods for Clinical Application
  186. The effect of stress on melatonin and serotonin in rat brain
  187. Human melatonin response to light at different times of the night
  188. Serotonin in Panic Disorder
  189. Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience
  190. Quantal melatonin suppression by exposure to low intensity light in man
  191. Relation Between Plasma Antidepressant Concentrations and Clinical Effects
  192. Platelet Serotonin Uptake in Panic Disorder: Comparison with Normal Controls and the Effect of Treatment
  193. A Case of Moclobemide Overdose
  194. A kinetic analysis of platelet monoamine oxidase activity in patients with panic attacks
  195. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans
  196. Urinary Tribulin Output in Patients with Panic Attacks
  197. Plasma Prolactin and Fluphenazine Concentrations in Patients receiving Fluphenazine Decanoate: Stability over Injection Intervals
  198. Platelet 3H-rauwolscine binding in patients with panic attacks
  199. Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease
  200. PLATELET MONOAMINE OXIDASE ACTIVITY IN PATIENTS WITH HUNTINGTON'S DISEASE
  201. The pineal hormone melatonin in panic disorder
  202. Plasma immunoreactive β-endorphin in dexamethasone suppressors and non-suppressors of cortisol
  203. The Dexamethasone Suppression Test in Panic Disorder
  204. Melatonin Rhythm in Human Plasma Saliva
  205. Platelet monoamine uptake in depression — primary or secondary phenomenon?
  206. Platelet monoamine oxidase: Low activity in cigarette smokers
  207. Low platelet monoamine oxidase and sensation seeking in males: an established relationship?
  208. Melatonin in panic disorder
  209. Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate)
  210. Plasma Melatonin Concentrations in Depression
  211. Platelet serotonin uptake in panic disorder
  212. A case of alprazolam-related hepatitis
  213. Anxiety and the Benzodiazepine Receptor
  214. Pharmacological Treatment of Panic Disorder
  215. Determination of tiapride in plasma by high-performance liquid chromatography
  216. The biological basis of anxiety
  217. Analysis of tricyclic antidepressant drugs in plasma and serum by chromatographic techniques
  218. Antidepressant therapy: benefits and risks in perspective
  219. A controlled study of a specific MAO a reversible inhibitor (R011-1163) and amitriptyline in depressive illness
  220. A study of the dexamethasone suppression test in hospitalized depressed patients
  221. Plasma concentrations of benzodiazepines — A review of clinical findings and implications
  222. Renal Function Related Changes in Lithium Kinetics
  223. Safety of zimeldine in overdose.
  224. Psychosis after withdrawal of steroid therapy
  225. Liver Impairment Associated with Nomifensine
  226. Zimeldine in depressive illness — efficacy and safety data
  227. Maprotiline in affective illness
  228. The pharmacokinetics of mianserin in elderly depressed patients
  229. Zimelidine: A placebo-controlled trial in depression
  230. Clinical Pharmacokinetics of Dothiepin
  231. Measurement of moclobamide, a new monoamine oxidase inhibitor, by gas chromatography with nitrogen-selective detection
  232. Doxepin and Visual Hallucinations
  233. Assessment of the antidepressant activity of dothiepin and its metabolites by preclinical tests
  234. Ligand binding and platelet uptake studies of loxapine, amoxapine and their 8-hydroxylated derivatives
  235. Pharmacokinetics of nomifensine after a single oral dose [letter]
  236. Monitoring and Interpretation of Antidepressant Plasma Concentrations
  237. Platelet monoamine oxidase activity and cigarette smoking
  238. Blood and plasma concentrations of dothiepin and its major metabolites and clinical response
  239. A pharmacokinetic study of mianserin
  240. The new psychiatry
  241. Determination of nomifensine plasma concentrations: a comparison of radioimmunoassay and gas chromatography.
  242. Metabolism and pharmacokinetics of dothiepin.
  243. MULTICENTRE EVALUATION OF MIANSERIN IN DEPRESSIVE ILLNESS
  244. Simultaneous measurement of dothiepin and its major metabolites in plasma and whole blood by gas chromatography—mass fragmentography
  245. Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: The effect of smoking
  246. Psychotherapeutic Drugs
  247. Viloxazine plasma concentrations and clinical response
  248. An evaluation of maprotiline intravenous kinetics and comparison of two oral doses
  249. Doxepin Plasma Levels and Anxiolytic Response
  250. Plasma Nomifensine Concentration
  251. Determination of viloxazine in plasma by GLC.
  252. PHARMACOKINETICS AND PLASMA LEVELS OF ANTIDEPRESSANTS IN THE ELDERLY
  253. Amitriptyline plasma concentration and clinical response.
  254. Interlaboratory comparison of nortriptyline levels
  255. A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY
  256. A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE
  257. Determination of therapeutic levels of butriptyline in plasma by gas-liquid chromatography
  258. The synthesis and characterization of azido and cyanato dithiocarbamato nitrosyl complexes of molybdenum : Reduction of coordinated azide in Azidobis(N,N-diethyldithiocarbamato)(dimethyl sulphoxide)nitrosylmolybdenum
  259. Reactivity of a coordinated nitrosyl in dinitrosylbis (N N′ diethyldithio-carbamato)molybdenum
  260. Reaction of dinitrogen oxide with Pentaammineaquaruthenium(II) and isolation of Pentaammine(dinitrogen oxide)ruthenium(II) complexes
  261. Iatrogenic psychosis
  262. Isotope Derivative Assays for Psychotropic Drugs
  263. Hypnosis in the Management of Stress and Anxiety Disorders
  264. Ethnic differences in psychotropic drug response and pharmacokinetics